ABUS vs EMN · P/E 5.4, rev $6.2M vs P/E 21, rev $9.38B
Arbutus Biopharma Corp (ABUS) versus Eastman Chemical Company (EMN) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Eastman Chemical Company (EMN) is a specialty chemicals company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported EMN revenue for 2024-12-31 was $9.38B. Net income was $908.0M. Revenue was up 1.9% from 2023-12-31 to 2024-12-31. EMN currently screens at market cap $8.21B and trailing P/E 20.8.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. EMN currently screens at market cap $8.21B and trailing P/E 20.8.
Not investment advice. Open the ABUS and EMN stock pages for the full models.
Not investment advice.